PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3382028-0 1988 Androgen receptor-deficient Tfm cells in the mosaic epididymis of sex-reversed mice heterozygous for Tfm: an autoradiographic study with [3H]-dihydrotestosterone and [3H]-estradiol. Dihydrotestosterone 142-161 androgen receptor Mus musculus 0-17 2811368-9 1989 In the area postrema and in accessory sex glands binding is inhibited by DHT but not by E2, indicating binding only to AR. Dihydrotestosterone 73-76 androgen receptor Mus musculus 119-121 2974815-5 1988 Further evidence for an action of the adrenal steroids through the androgen receptor is indicated by competition of [3H]testosterone uptake in the tumor cells at the following IC50 values: 0.21 nM, 0.63 nM, 50 nM, 75 nM and 680 nM for DHT, testosterone, delta 4-dione, delta 5-diol and DHEA, respectively. Dihydrotestosterone 235-238 androgen receptor Mus musculus 67-84 3382028-7 1988 Our observations demonstrate that Tfm cells in the mosaic epididymis selectively lack nuclear dihydrotestosterone-binding sites, whereas estradiol-binding sites are intact. Dihydrotestosterone 94-113 androgen receptor Mus musculus 34-37 6542571-14 1984 If so, dihydrotestosterone performs one of its major actions independent of the androgen receptor. Dihydrotestosterone 7-26 androgen receptor Mus musculus 80-97 3754248-2 1986 Specific binding sites for 3H dihydrotestosterone are demonstrated by autoradiography in brain nuclei of sex reversed mice heterozygous for testicular feminization (Tfm) which are phenotypically intersexes with testes and accessory sex glands that consist of a mosaic of androgen insensitive Tfm cells which lack specific dihydrotestosterone binding and androgen sensitive normal cells. Dihydrotestosterone 30-49 androgen receptor Mus musculus 165-168 3754248-2 1986 Specific binding sites for 3H dihydrotestosterone are demonstrated by autoradiography in brain nuclei of sex reversed mice heterozygous for testicular feminization (Tfm) which are phenotypically intersexes with testes and accessory sex glands that consist of a mosaic of androgen insensitive Tfm cells which lack specific dihydrotestosterone binding and androgen sensitive normal cells. Dihydrotestosterone 30-49 androgen receptor Mus musculus 292-295 6706245-1 1984 Relative binding affinities (RBA) for the androgen receptor were estimated for levonorgestrel, progesterone, dihydrotestosterone, cyproterone acetate, 17 alpha-propylmesterolone and 3-keto-desogestrel (13-ethinyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol-3-one) which is the biological active metabolite of desogestrel. Dihydrotestosterone 109-128 androgen receptor Mus musculus 42-59 179788-10 1976 For the interaction of estradiol with the androgen receptor, the Ki is 8-9 X 10(-9)M. The decrease in the number of DHT binding sites in the brain of tfm/y male-female mice without a concomitant decrease in estradiol binding sites, and the different specificities of the two sites, point to the existence of distinct androgen and estrogen receptor molecules in mouse brain cytosol. Dihydrotestosterone 116-119 androgen receptor Mus musculus 42-59 7285862-6 1981 In castrate mice, however, the administration of 200 micrograms DHT completely abolished the thymic hypertrophy otherwise seen post castration and significantly increased the total thymic content of androgen receptor. Dihydrotestosterone 64-67 androgen receptor Mus musculus 199-216 7028030-4 1981 Loss of androgen receptor did not affect basal renin activity but did prevent enhancement by DHT. Dihydrotestosterone 93-96 androgen receptor Mus musculus 8-25 590404-1 1977 The insensitivity of Tfm mutant mice to androgens is due to a greatly diminished ability to bind 5alpha-dihydrotestosterone to androgen-binding receptors in the cytoplasm of target tissues. Dihydrotestosterone 97-123 androgen receptor Mus musculus 21-24 590404-5 1977 The Tfm mutant was not stimulated to incorporate 59Fe, suggesting that androgen-binding receptors mediate this hemopoietic action of 5alpha-DHT. Dihydrotestosterone 133-143 androgen receptor Mus musculus 4-7 32959393-5 2021 First, we evaluated the expression of the androgen receptor (AR), the transcription factor activated by DHT that mediates the physiological effects of androgens, in NPCs. Dihydrotestosterone 104-107 androgen receptor Mus musculus 42-59 33719566-4 2021 Activation of androgen receptor (AR) using 5alpha-Dihydrotestosterone (5a-DHT, AR agonist) resulted in decreased Th2/Th17 inflammation and remodeling associated changes, resulting in improved lung function compared to MA alone challenged mice, especially in GDX mice. Dihydrotestosterone 43-69 androgen receptor Mus musculus 14-31 33719566-4 2021 Activation of androgen receptor (AR) using 5alpha-Dihydrotestosterone (5a-DHT, AR agonist) resulted in decreased Th2/Th17 inflammation and remodeling associated changes, resulting in improved lung function compared to MA alone challenged mice, especially in GDX mice. Dihydrotestosterone 43-69 androgen receptor Mus musculus 33-35 33719566-4 2021 Activation of androgen receptor (AR) using 5alpha-Dihydrotestosterone (5a-DHT, AR agonist) resulted in decreased Th2/Th17 inflammation and remodeling associated changes, resulting in improved lung function compared to MA alone challenged mice, especially in GDX mice. Dihydrotestosterone 43-69 androgen receptor Mus musculus 79-81 33719566-4 2021 Activation of androgen receptor (AR) using 5alpha-Dihydrotestosterone (5a-DHT, AR agonist) resulted in decreased Th2/Th17 inflammation and remodeling associated changes, resulting in improved lung function compared to MA alone challenged mice, especially in GDX mice. Dihydrotestosterone 71-77 androgen receptor Mus musculus 14-31 33719566-4 2021 Activation of androgen receptor (AR) using 5alpha-Dihydrotestosterone (5a-DHT, AR agonist) resulted in decreased Th2/Th17 inflammation and remodeling associated changes, resulting in improved lung function compared to MA alone challenged mice, especially in GDX mice. Dihydrotestosterone 71-77 androgen receptor Mus musculus 33-35 33517191-0 2021 Dihydrotestosterone-induced hair regrowth inhibition by activating androgen receptor in C57BL6 mice simulates androgenetic alopecia. Dihydrotestosterone 0-19 androgen receptor Mus musculus 67-84 33517191-4 2021 The present study describes androgen receptor (AR) in C57BL/6 mouse hair follicles that can be activated by dihydrotestosterone (DHT) and translocate to the nucleus. Dihydrotestosterone 108-127 androgen receptor Mus musculus 28-45 33517191-4 2021 The present study describes androgen receptor (AR) in C57BL/6 mouse hair follicles that can be activated by dihydrotestosterone (DHT) and translocate to the nucleus. Dihydrotestosterone 108-127 androgen receptor Mus musculus 47-49 33517191-4 2021 The present study describes androgen receptor (AR) in C57BL/6 mouse hair follicles that can be activated by dihydrotestosterone (DHT) and translocate to the nucleus. Dihydrotestosterone 129-132 androgen receptor Mus musculus 28-45 33517191-4 2021 The present study describes androgen receptor (AR) in C57BL/6 mouse hair follicles that can be activated by dihydrotestosterone (DHT) and translocate to the nucleus. Dihydrotestosterone 129-132 androgen receptor Mus musculus 47-49 33517191-7 2021 These effects of DHT could be partly reversed by the AR antagonist bicalutamide. Dihydrotestosterone 17-20 androgen receptor Mus musculus 53-55 32959393-5 2021 First, we evaluated the expression of the androgen receptor (AR), the transcription factor activated by DHT that mediates the physiological effects of androgens, in NPCs. Dihydrotestosterone 104-107 androgen receptor Mus musculus 61-63 32959393-7 2021 AR activation mediated by DHT treatment strongly increased the proliferation of NPCs and reduced their propensity to differentiate into neurons. Dihydrotestosterone 26-29 androgen receptor Mus musculus 0-2 31219567-1 2019 Androgens (testosterone and DHT) increase adult hippocampal neurogenesis by increasing survival of new neurons in male rats and mice via an androgen receptor pathway, but it is not known whether androgens regulate neurogenesis in female rats and whether the effect is age-dependent. Dihydrotestosterone 28-31 androgen receptor Mus musculus 140-157 32856205-3 2021 PolyQ-AR is converted to a toxic species upon binding to its natural ligands, testosterone, and dihydrotestosterone (DHT). Dihydrotestosterone 96-115 androgen receptor Mus musculus 6-8 32856205-3 2021 PolyQ-AR is converted to a toxic species upon binding to its natural ligands, testosterone, and dihydrotestosterone (DHT). Dihydrotestosterone 117-120 androgen receptor Mus musculus 6-8 32758727-13 2020 After inhibiting NLRP3, dihydrotestosterone (DHT)-treated GCs demonstrated markedly decreased NLRP3, the inflammasome adapter protein ASC, C-terminal fragment of gasdermin D (GSDMD-C), AR and Cyp19alpha1 at the protein level. Dihydrotestosterone 24-43 androgen receptor Mus musculus 185-187 32758727-13 2020 After inhibiting NLRP3, dihydrotestosterone (DHT)-treated GCs demonstrated markedly decreased NLRP3, the inflammasome adapter protein ASC, C-terminal fragment of gasdermin D (GSDMD-C), AR and Cyp19alpha1 at the protein level. Dihydrotestosterone 45-48 androgen receptor Mus musculus 185-187 32311143-3 2020 DESIGN AND METHODS: To identify the androgen signalling pathway, we treated male mice lacking the second zinc finger of the DNA binding domain of the AR (AR ZF2 ) with non-aromatizable 5alpha-dihydrotestosterone (5alpha-DHT), or aromatizable testosterone. Dihydrotestosterone 185-211 androgen receptor Mus musculus 150-152 32311143-3 2020 DESIGN AND METHODS: To identify the androgen signalling pathway, we treated male mice lacking the second zinc finger of the DNA binding domain of the AR (AR ZF2 ) with non-aromatizable 5alpha-dihydrotestosterone (5alpha-DHT), or aromatizable testosterone. Dihydrotestosterone 213-223 androgen receptor Mus musculus 150-152 32311143-9 2020 Female wild-type mice reconstituted with AR ZF2 bone marrow cells remained responsive to 5alpha-DHT. Dihydrotestosterone 89-99 androgen receptor Mus musculus 41-43 31669915-7 2019 Further analysis showed that the androgen receptor (Ar) located in the cytosol of MIN6 cells and translocated to the nucleus after DHT treatment. Dihydrotestosterone 131-134 androgen receptor Mus musculus 33-50 31669915-7 2019 Further analysis showed that the androgen receptor (Ar) located in the cytosol of MIN6 cells and translocated to the nucleus after DHT treatment. Dihydrotestosterone 131-134 androgen receptor Mus musculus 52-54 31393859-7 2019 DHT treated control mice with intact pituitary Ar (Con-DHT) exhibit disrupted estrous cyclicity and fertility with reduced pituitary responsiveness to GnRH at the level of both calcium signaling and LH secretion. Dihydrotestosterone 0-3 androgen receptor Mus musculus 47-49 31393859-7 2019 DHT treated control mice with intact pituitary Ar (Con-DHT) exhibit disrupted estrous cyclicity and fertility with reduced pituitary responsiveness to GnRH at the level of both calcium signaling and LH secretion. Dihydrotestosterone 55-58 androgen receptor Mus musculus 47-49 29778874-2 2018 DHT is the key ligand for androgen receptor (AR) in the prostate. Dihydrotestosterone 0-3 androgen receptor Mus musculus 26-43 29778874-2 2018 DHT is the key ligand for androgen receptor (AR) in the prostate. Dihydrotestosterone 0-3 androgen receptor Mus musculus 45-47 27330033-6 2016 RESULTS: Dihydrotestosterone increased bladder cancer cell proliferation, migration, and invasion indicating that endogenous or exogenous AR was functional. Dihydrotestosterone 9-28 androgen receptor Mus musculus 138-140 29491216-7 2018 The phosphorylated Akt protein level was increased by YK11 and DHT treatment, suggesting that YK11 activates Akt-signaling via non-genomic signaling of AR. Dihydrotestosterone 63-66 androgen receptor Mus musculus 152-154 28360090-7 2017 Testosterone can (1) activate the estrogen receptor after its aromatization into 17beta-estradiol or (2) be reduced into dihydrotestosterone, a nonaromatizable androgen that activates the androgen receptor. Dihydrotestosterone 121-140 androgen receptor Mus musculus 188-205 28235766-5 2017 Here we demonstrate that treatment with a small-molecule Sigma1 inhibitor prevented 5alpha- dihydrotestosterone-mediated nuclear translocation of AR and induced proteasomal degradation of AR and ARV, suppressing the transcriptional activity and protein levels of both full-length and splice-variant AR. Dihydrotestosterone 84-111 androgen receptor Mus musculus 146-148 28320971-5 2017 Global loss of the AR reveals that AR signaling is required for all DHT-induced features of PCOS. Dihydrotestosterone 68-71 androgen receptor Mus musculus 19-21 28320971-5 2017 Global loss of the AR reveals that AR signaling is required for all DHT-induced features of PCOS. Dihydrotestosterone 68-71 androgen receptor Mus musculus 35-37 27866534-6 2016 Conclusion: DHT at concentrations of 1x10-9 mol/L and 1x10-8 mol/L decreases LOX-1 expression and foam cell formation via AR. Dihydrotestosterone 12-15 androgen receptor Mus musculus 122-124 26963473-6 2016 Treatment with DHT increased uterine weight, the area of the endometrial compartment and immunoexpression of the androgen receptor in the luminal and glandular epithelium. Dihydrotestosterone 15-18 androgen receptor Mus musculus 113-130 26393303-12 2015 In conclusion, both DHT and GTx-024 target AR pathways in the satellite cell lineage, but cells outside this lineage also contribute to the anabolic effects of androgens. Dihydrotestosterone 20-23 androgen receptor Mus musculus 43-45 26335395-3 2015 In addition, to clarify the mechanism underlying its tissue selectivity, we performed comprehensive cofactor recruitment analysis of androgen receptor using TSAA-291 and dihydrotestosterone (DHT), an endogenous androgen. Dihydrotestosterone 170-189 androgen receptor Mus musculus 133-150 26335395-3 2015 In addition, to clarify the mechanism underlying its tissue selectivity, we performed comprehensive cofactor recruitment analysis of androgen receptor using TSAA-291 and dihydrotestosterone (DHT), an endogenous androgen. Dihydrotestosterone 191-194 androgen receptor Mus musculus 133-150 26322830-7 2015 In reporter gene assays, CpdA failed to induce GR transactivation, whereas it antagonized dihydrotestosterone-enhanced AR transactivation. Dihydrotestosterone 90-109 androgen receptor Mus musculus 119-121 25586052-8 2015 CYP3A5 siRNA inhibited growth in response to DHT and R1881 treatment in LNCaP and C4-2 by decreasing nuclear AR localization and resulting in diminished PSA and TMPRSS2 expression. Dihydrotestosterone 45-48 androgen receptor Mus musculus 109-111 25550469-6 2015 Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis. Dihydrotestosterone 28-47 androgen receptor Mus musculus 17-19 24945110-1 2014 Androgens including testosterone and dihydrotestosterone play important roles on brain structure and function, either directly through androgen receptor or indirectly through estrogen receptors, which need coactivators for their transcription activation. Dihydrotestosterone 37-56 androgen receptor Mus musculus 135-152 26464961-8 2014 Interestingly, treatment of female mice with the potent androgen receptor agonist DHT had no effect on ischemic injury and did not permit CTZ neuroprotection. Dihydrotestosterone 82-85 androgen receptor Mus musculus 56-73 24467187-1 2014 Androgens (testosterone and dihydrotestosterone) acting via the androgen receptor (AR) are required for male sexual differentiation, and also regulate the development of many other tissues including muscle, fat and bone. Dihydrotestosterone 28-47 androgen receptor Mus musculus 64-81 25232488-4 2014 Androgen (R1881, dihydrotestosterone) treatment in SVHUC immortalized normal urothelial cells stably expressing AR (SVHUC-AR) decreased GATA3 expression at both mRNA and protein levels, which was abolished by anti-androgens. Dihydrotestosterone 17-36 androgen receptor Mus musculus 112-114 25232488-4 2014 Androgen (R1881, dihydrotestosterone) treatment in SVHUC immortalized normal urothelial cells stably expressing AR (SVHUC-AR) decreased GATA3 expression at both mRNA and protein levels, which was abolished by anti-androgens. Dihydrotestosterone 17-36 androgen receptor Mus musculus 116-124 24467187-1 2014 Androgens (testosterone and dihydrotestosterone) acting via the androgen receptor (AR) are required for male sexual differentiation, and also regulate the development of many other tissues including muscle, fat and bone. Dihydrotestosterone 28-47 androgen receptor Mus musculus 83-85 24020966-8 2013 Interestingly, the androgen receptor level in the brain was increased by chronic treatment with the same combination treatment, ACP-105 and AC-186, not seen with DHT or ACP-105 alone. Dihydrotestosterone 162-165 androgen receptor Mus musculus 19-36 21872641-2 2012 In cultured genital skin fibroblasts, the mutant AR(DeltaZF2) has normal ligand binding ability, phosphorylates ERK-1/2 in response to 1 min DHT treatment (blocked by the AR antagonist bicalutamide), but has reduced androgen-dependent nuclear localization compared to wildtype (WT). Dihydrotestosterone 141-144 androgen receptor Mus musculus 49-51 23780684-8 2013 Further analysis suggested that increased expression of HSD3B1 and reduced expression of androgen receptor (AR) promoted adaptation to androgen-abundant conditions, as indicated by the increased conversion of DHT into 3beta-diol by HSD3B1 and AR signal reduction. Dihydrotestosterone 209-212 androgen receptor Mus musculus 89-106 23780684-8 2013 Further analysis suggested that increased expression of HSD3B1 and reduced expression of androgen receptor (AR) promoted adaptation to androgen-abundant conditions, as indicated by the increased conversion of DHT into 3beta-diol by HSD3B1 and AR signal reduction. Dihydrotestosterone 209-212 androgen receptor Mus musculus 108-110 23780684-8 2013 Further analysis suggested that increased expression of HSD3B1 and reduced expression of androgen receptor (AR) promoted adaptation to androgen-abundant conditions, as indicated by the increased conversion of DHT into 3beta-diol by HSD3B1 and AR signal reduction. Dihydrotestosterone 209-212 androgen receptor Mus musculus 243-245 22086872-5 2013 Dihydrotestosterone (DHT) treatment in SVHUC-AR reduced mRNA expression of all the UGT1A subtypes (19-75% decrease), and hydroxyflutamide antagonized the DHT effects. Dihydrotestosterone 0-19 androgen receptor Mus musculus 45-47 22086872-5 2013 Dihydrotestosterone (DHT) treatment in SVHUC-AR reduced mRNA expression of all the UGT1A subtypes (19-75% decrease), and hydroxyflutamide antagonized the DHT effects. Dihydrotestosterone 21-24 androgen receptor Mus musculus 45-47 23995658-1 2013 The myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist, (17alpha,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), as well as by dihydrotestosterone (DHT). Dihydrotestosterone 254-273 androgen receptor Mus musculus 77-94 23995658-1 2013 The myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist, (17alpha,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), as well as by dihydrotestosterone (DHT). Dihydrotestosterone 254-273 androgen receptor Mus musculus 96-98 23995658-1 2013 The myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist, (17alpha,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), as well as by dihydrotestosterone (DHT). Dihydrotestosterone 275-278 androgen receptor Mus musculus 77-94 23995658-1 2013 The myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist, (17alpha,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), as well as by dihydrotestosterone (DHT). Dihydrotestosterone 275-278 androgen receptor Mus musculus 96-98 22910580-10 2012 Cortical thickness also decreased with ORX but immediate DHT treatment was effective to increase thickness only in WT mice, likely due to expansion of marrow volume in both AR-tg lines. Dihydrotestosterone 57-60 androgen receptor Mus musculus 173-175 22910580-13 2012 Improvement in cancellous bone architecture was seen with immediate DHT replacement that was enhanced in AR transgenic lines compared to WT. Dihydrotestosterone 68-71 androgen receptor Mus musculus 105-107 21872641-5 2012 Cortical bone growth was suppressed by DHT in AR(DeltaZF2) mice (6% decrease in periosteal and 7% decrease in medullary circumference vs untreated AR(DeltaZF2) males). Dihydrotestosterone 39-42 androgen receptor Mus musculus 46-48 21872641-5 2012 Cortical bone growth was suppressed by DHT in AR(DeltaZF2) mice (6% decrease in periosteal and 7% decrease in medullary circumference vs untreated AR(DeltaZF2) males). Dihydrotestosterone 39-42 androgen receptor Mus musculus 147-149 21374593-2 2012 Recent in vitro studies have shown that dihydrotestosterone and anabolic steroids have functions in promoting the proliferation and differentiation of the mouse skeletal muscle myoblast C2C12 cell line through the classical androgen receptor (AR) signaling pathway. Dihydrotestosterone 40-59 androgen receptor Mus musculus 224-241 21374593-2 2012 Recent in vitro studies have shown that dihydrotestosterone and anabolic steroids have functions in promoting the proliferation and differentiation of the mouse skeletal muscle myoblast C2C12 cell line through the classical androgen receptor (AR) signaling pathway. Dihydrotestosterone 40-59 androgen receptor Mus musculus 243-245 21822606-2 2012 Testosterone 5alpha-reductase is an enzyme catalyzing the conversion of testosterone to dihydrotestosterone, which possesses high affinity for the androgen receptor. Dihydrotestosterone 88-107 androgen receptor Mus musculus 147-164 21793043-9 2011 In targeted AR transgenic mice, DHT treatment increased lean and reduced fat mass to sham levels. Dihydrotestosterone 32-35 androgen receptor Mus musculus 12-14 24323653-7 2011 Our results show (1) ischemia alters the expression of AR by decreasing AR mRNA levels, (2) AR overexpression is protective in vivo against MCAO in intact and castrated AR-Tg mice and in vitro against oxidative and apoptotic stressors in AR-PC12 cells, and (3) DHT does not enhance the protection triggered by AR overexpression in AR-Tg castrated mice nor in AR-PC12 cells. Dihydrotestosterone 261-264 androgen receptor Mus musculus 55-57 21839661-11 2011 These observations suggest that DHT may decrease IGF-I production in dermal papillae by inhibiting sensory neuron stimulation through interaction with the androgen receptor, thereby inhibiting hair growth in mice. Dihydrotestosterone 32-35 androgen receptor Mus musculus 155-172 21731732-1 2011 Androgens are important regulators of bone mass but the relative importance of testosterone (T) versus dihydrotestosterone (DHT) for the activation of the androgen receptor (AR) in bone is unknown. Dihydrotestosterone 103-122 androgen receptor Mus musculus 155-172 21220406-3 2011 In this study, we demonstrate that in epididymal cells, 5alpha-dihydrotestosterone (DHT) can cause an alternative and rapid response that is independent of AR-DNA interactions and is mediated by activation of signaling pathways through the AR. Dihydrotestosterone 56-82 androgen receptor Mus musculus 156-158 21220406-3 2011 In this study, we demonstrate that in epididymal cells, 5alpha-dihydrotestosterone (DHT) can cause an alternative and rapid response that is independent of AR-DNA interactions and is mediated by activation of signaling pathways through the AR. Dihydrotestosterone 56-82 androgen receptor Mus musculus 240-242 21220406-3 2011 In this study, we demonstrate that in epididymal cells, 5alpha-dihydrotestosterone (DHT) can cause an alternative and rapid response that is independent of AR-DNA interactions and is mediated by activation of signaling pathways through the AR. Dihydrotestosterone 84-87 androgen receptor Mus musculus 156-158 21220406-3 2011 In this study, we demonstrate that in epididymal cells, 5alpha-dihydrotestosterone (DHT) can cause an alternative and rapid response that is independent of AR-DNA interactions and is mediated by activation of signaling pathways through the AR. Dihydrotestosterone 84-87 androgen receptor Mus musculus 240-242 21731732-1 2011 Androgens are important regulators of bone mass but the relative importance of testosterone (T) versus dihydrotestosterone (DHT) for the activation of the androgen receptor (AR) in bone is unknown. Dihydrotestosterone 103-122 androgen receptor Mus musculus 174-176 21731732-1 2011 Androgens are important regulators of bone mass but the relative importance of testosterone (T) versus dihydrotestosterone (DHT) for the activation of the androgen receptor (AR) in bone is unknown. Dihydrotestosterone 124-127 androgen receptor Mus musculus 155-172 21731732-1 2011 Androgens are important regulators of bone mass but the relative importance of testosterone (T) versus dihydrotestosterone (DHT) for the activation of the androgen receptor (AR) in bone is unknown. Dihydrotestosterone 124-127 androgen receptor Mus musculus 174-176 21731732-2 2011 5alpha-reductase is responsible for the irreversible conversion of T to the more potent AR activator DHT. Dihydrotestosterone 101-104 androgen receptor Mus musculus 88-90 20937368-9 2010 Reporter gene analysis further revealed that tamoxifen repressed the 5alpha-dihydrotestosterone-induced activation of the AR and the intrinsic transactivation function of RORalpha1, HNF4alpha, and NR2F1. Dihydrotestosterone 69-95 androgen receptor Mus musculus 122-124 20557886-3 2010 More recently, it has been shown that the transformation of the dihydrotestosterone to 5alpha-androstane-3alpha,17beta-diol (3alpha-diol) and 5alpha-androstane-3beta,17beta-diol (3beta-Adiol), generates two molecules unable to bind the androgen receptor, but with a high affinity for the estrogen receptors (ERs) in particular the beta isoform. Dihydrotestosterone 64-83 androgen receptor Mus musculus 236-253 20427482-11 2010 Such suppressive effects of DHT on foam cell formation and cytokine expression were not observed in cultured macrophages prepared from male AR-null mice, suggesting an involvement of AR in the mechanism. Dihydrotestosterone 28-31 androgen receptor Mus musculus 183-185 20605780-8 2010 Direct measurement of AR activity was performed in mouse embryonic fibroblast cells treated with dihydrotestosterone or synthetic agonist R1881. Dihydrotestosterone 97-116 androgen receptor Mus musculus 22-24 20435684-9 2010 This effect is less marked than that of AR activation by DHT treatment, which completely prevented the effect of orx on muscle mass and was partly, but not fully, mediated via alternative pathways. Dihydrotestosterone 57-60 androgen receptor Mus musculus 40-42 20233794-9 2010 This effect is AR mediated, because treatment with the AR antagonist hydroxyflutamide inhibited the effect of dihydrotestosterone on hair growth. Dihydrotestosterone 110-129 androgen receptor Mus musculus 15-17 20154177-5 2010 Organ and primary cell cultures of gubernacula showed that 5alpha-dihydrotestosterone (DHT) upregulated the expression of Rxfp2 which was abolished by the addition of an AR antagonist, flutamide. Dihydrotestosterone 59-85 androgen receptor Mus musculus 170-172 20154177-5 2010 Organ and primary cell cultures of gubernacula showed that 5alpha-dihydrotestosterone (DHT) upregulated the expression of Rxfp2 which was abolished by the addition of an AR antagonist, flutamide. Dihydrotestosterone 87-90 androgen receptor Mus musculus 170-172 19895913-9 2010 In addition, nonaromatizable dihydrotestosterone (DHT) inhibited osteoblast proliferation, differentiation and several indices of mineralization, including mineral accumulation and mineralized nodule formation in primary cultures from both wild-type and AR-transgenic mice. Dihydrotestosterone 29-48 androgen receptor Mus musculus 254-256 19895913-9 2010 In addition, nonaromatizable dihydrotestosterone (DHT) inhibited osteoblast proliferation, differentiation and several indices of mineralization, including mineral accumulation and mineralized nodule formation in primary cultures from both wild-type and AR-transgenic mice. Dihydrotestosterone 50-53 androgen receptor Mus musculus 254-256 19866465-8 2010 Androgens- testosterone and dihydrotestosterone- coincidently increase at CRPC to physiologically relevant levels leading to the induction of AR expression and PSA production. Dihydrotestosterone 28-47 androgen receptor Mus musculus 142-144 19015999-0 2009 Androgen receptor is expressed in murine choroid plexus and downregulated by 5alpha-dihydrotestosterone in male and female mice. Dihydrotestosterone 77-103 androgen receptor Mus musculus 0-17 19855091-5 2009 The dose-response curve of DHT-stimulated C4-2 colony formation was shifted by shHDAC6 such that approximately 10-fold higher concentration of DHT is required, indicating a requirement for HDAC6 in AR hypersensitivity. Dihydrotestosterone 27-30 androgen receptor Mus musculus 198-200 19676081-4 2009 This greatly reduces the amount of the active ligand DHT available for binding to the androgen receptor (AR) and stimulating proliferation, making this a good candidate for chemoprevention of prostate cancer. Dihydrotestosterone 53-56 androgen receptor Mus musculus 86-103 19676081-4 2009 This greatly reduces the amount of the active ligand DHT available for binding to the androgen receptor (AR) and stimulating proliferation, making this a good candidate for chemoprevention of prostate cancer. Dihydrotestosterone 53-56 androgen receptor Mus musculus 105-107 19389811-2 2009 We dissected AR-mediated repression of Runx2 in dihydrotestosterone (DHT)-treated osteoblastic and PCa cells using reporter assays and endogenous Runx2 target genes. Dihydrotestosterone 48-67 androgen receptor Mus musculus 13-15 19389811-2 2009 We dissected AR-mediated repression of Runx2 in dihydrotestosterone (DHT)-treated osteoblastic and PCa cells using reporter assays and endogenous Runx2 target genes. Dihydrotestosterone 69-72 androgen receptor Mus musculus 13-15 19015999-7 2009 In addition, the response of AR to 5alpha-dihydrotestosterone (DHT) in castrated male and female mice subjected to DHT replacement was analyzed. Dihydrotestosterone 35-61 androgen receptor Mus musculus 29-31 19015999-7 2009 In addition, the response of AR to 5alpha-dihydrotestosterone (DHT) in castrated male and female mice subjected to DHT replacement was analyzed. Dihydrotestosterone 63-66 androgen receptor Mus musculus 29-31 19015999-9 2009 Moreover, we demonstrate that AR is downregulated by DHT in mice CPs. Dihydrotestosterone 53-56 androgen receptor Mus musculus 30-32 18948405-3 2009 Incubation of mesenchymal multipotent C3H 10T1/2 cells with testosterone and dihydrotestosterone promoted nuclear translocation of androgen receptor (AR)/beta-catenin complex and physical interaction of AR, beta-catenin, and T-cell factor-4 (TCF-4). Dihydrotestosterone 77-96 androgen receptor Mus musculus 131-148 18948405-3 2009 Incubation of mesenchymal multipotent C3H 10T1/2 cells with testosterone and dihydrotestosterone promoted nuclear translocation of androgen receptor (AR)/beta-catenin complex and physical interaction of AR, beta-catenin, and T-cell factor-4 (TCF-4). Dihydrotestosterone 77-96 androgen receptor Mus musculus 150-152 18948405-3 2009 Incubation of mesenchymal multipotent C3H 10T1/2 cells with testosterone and dihydrotestosterone promoted nuclear translocation of androgen receptor (AR)/beta-catenin complex and physical interaction of AR, beta-catenin, and T-cell factor-4 (TCF-4). Dihydrotestosterone 77-96 androgen receptor Mus musculus 203-205 19176322-7 2009 Androgen-induced calcification in the innominate artery was observed with up-regulation of local androgen receptor (AR) expression in response to T and dihydrotestosterone for both males and females but neither androgen influenced innominate artery estrogen receptor (ER)-alpha or -beta expression in either sex. Dihydrotestosterone 152-171 androgen receptor Mus musculus 97-114 19176322-7 2009 Androgen-induced calcification in the innominate artery was observed with up-regulation of local androgen receptor (AR) expression in response to T and dihydrotestosterone for both males and females but neither androgen influenced innominate artery estrogen receptor (ER)-alpha or -beta expression in either sex. Dihydrotestosterone 152-171 androgen receptor Mus musculus 116-118 18794357-6 2008 Treating cells with the AR ligand, dihydrotestosterone (DHT), triggered the reduction of E-cadherin expression and induced changes in cell morphology from an epithelial-like to a mesenchymal-like appearance. Dihydrotestosterone 35-54 androgen receptor Mus musculus 24-26 18794357-6 2008 Treating cells with the AR ligand, dihydrotestosterone (DHT), triggered the reduction of E-cadherin expression and induced changes in cell morphology from an epithelial-like to a mesenchymal-like appearance. Dihydrotestosterone 56-59 androgen receptor Mus musculus 24-26 18794357-7 2008 When nonmetastatic breast cancer cells expressing cytoplasmic AR were transplanted into mice and the mice were treated with DHT, tumors were detected at metastatic sites, whereas no tumors were detected in transplanted mice without DHT treatment. Dihydrotestosterone 124-127 androgen receptor Mus musculus 62-64 18794357-7 2008 When nonmetastatic breast cancer cells expressing cytoplasmic AR were transplanted into mice and the mice were treated with DHT, tumors were detected at metastatic sites, whereas no tumors were detected in transplanted mice without DHT treatment. Dihydrotestosterone 232-235 androgen receptor Mus musculus 62-64 18547308-0 2008 Dihydrotestosterone inhibits murine hair growth via the androgen receptor. Dihydrotestosterone 0-19 androgen receptor Mus musculus 56-73 19092298-8 2008 However, treatment of differentiated C2C12-AR myotubes with 100 nM DHT for 3 days caused a 20% increase in total protein content vs vehicle treatment (p<0.05). Dihydrotestosterone 67-70 androgen receptor Mus musculus 43-45 18467440-10 2008 Our data demonstrate that organization of social and olfactory preferences in mice can be affected by perinatal DHT and lends support to the role of androgen receptor in organization of sexual differentiation of brain and behaviors. Dihydrotestosterone 112-115 androgen receptor Mus musculus 149-166 16403089-6 2006 Treatment of GDX animals with dihydrotestosterone (DHT) or dehydroepiandrosterone (DHEA) increases AR expression, while 17beta-estradiol (E2) decreases the stimulatory effect of DHT and DHEA. Dihydrotestosterone 30-49 androgen receptor Mus musculus 99-101 17641240-6 2007 When dihydrotestosterone is added to the medium, the androgen receptor is stabilized, is imported to the nucleus, and drives differentiation to a luminal cell-like phenotype. Dihydrotestosterone 5-24 androgen receptor Mus musculus 53-70 16413235-4 2006 AR-MC3T3-E1 cells, with androgen receptor (AR) overexpression controlled by the type I collagen promoter, were treated with the non-aromatizable androgen 5alpha-dihydrotestosterone (DHT). Dihydrotestosterone 154-180 androgen receptor Mus musculus 0-2 16413235-6 2006 Transactivation of AR by DHT enhanced apoptosis while 17beta-estradiol (E(2)) treatment reduced apoptosis in both proliferating preosteoblasts and mature osteocyte-like cells. Dihydrotestosterone 25-28 androgen receptor Mus musculus 19-21 16403089-6 2006 Treatment of GDX animals with dihydrotestosterone (DHT) or dehydroepiandrosterone (DHEA) increases AR expression, while 17beta-estradiol (E2) decreases the stimulatory effect of DHT and DHEA. Dihydrotestosterone 51-54 androgen receptor Mus musculus 99-101 16403089-9 2006 CONCLUSIONS: The present data show gender differences and demonstrate that DHT, E2 and DHEA exert specific effects on the expression of AR and ERalpha in mouse sebocytes. Dihydrotestosterone 75-78 androgen receptor Mus musculus 136-138 16210377-11 2006 Testosterone and dihydrotestosterone inhibit adipocyte differentiation in vitro through an AR-mediated nuclear translocation of beta-catenin and activation of downstream Wnt signaling. Dihydrotestosterone 17-36 androgen receptor Mus musculus 91-93 15177002-14 2004 In addition, small interfering RNA against androgen receptor (siRNA-AR) prevented DHT-induced Akt phosphorylation and cell growth. Dihydrotestosterone 82-85 androgen receptor Mus musculus 43-60 15684350-4 2005 On the other hand, THG is more potent than DHT in binding to the androgen receptor, while, under in vivo conditions, THG possesses 20% of the potency of DHT in stimulating prostate, seminal vesicle and levator ani muscle weight in the mouse. Dihydrotestosterone 43-46 androgen receptor Mus musculus 65-82 15664454-5 2005 By observation of androgen receptor (AR)-tagged with green fluorescent protein under a confocal laser scanning microscope, we found that Tob1 inhibits the nuclear foci formation of dihydrotestosterone-bound AR. Dihydrotestosterone 181-200 androgen receptor Mus musculus 18-35 15664454-5 2005 By observation of androgen receptor (AR)-tagged with green fluorescent protein under a confocal laser scanning microscope, we found that Tob1 inhibits the nuclear foci formation of dihydrotestosterone-bound AR. Dihydrotestosterone 181-200 androgen receptor Mus musculus 37-39 15664454-5 2005 By observation of androgen receptor (AR)-tagged with green fluorescent protein under a confocal laser scanning microscope, we found that Tob1 inhibits the nuclear foci formation of dihydrotestosterone-bound AR. Dihydrotestosterone 181-200 androgen receptor Mus musculus 207-209 12960001-9 2003 Therefore, testosterone and DHT regulate lineage determination in mesenchymal pluripotent cells by promoting their commitment to the myogenic lineage and inhibiting their differentiation into the adipogenic lineage through an androgen receptor-mediated pathway. Dihydrotestosterone 28-31 androgen receptor Mus musculus 226-243 14612401-4 2003 The acetylation of the AR is induced by ligand dihydrotestosterone and by histone deacetylase (HDAC) inhibitors in living cells. Dihydrotestosterone 47-66 androgen receptor Mus musculus 23-25 12960001-7 2003 Androgen receptor mRNA and protein levels were low at baseline but increased after testosterone or DHT treatment. Dihydrotestosterone 99-102 androgen receptor Mus musculus 0-17 11226426-6 2001 Hydroxyflutamide, an androgen receptor antagonist, concentration-dependently antagonized the inhibitory effects of testosterone as well as DHT on PTH-stimulated osteoclast formation. Dihydrotestosterone 139-142 androgen receptor Mus musculus 21-38 12403848-6 2002 The inhibition of forskolin-stimulated cAMP accumulation by DHT was blocked by hydroxyflutamide, a specific inhibitor of the nuclear AR. Dihydrotestosterone 60-63 androgen receptor Mus musculus 133-135 11985887-2 2002 It competitively antagonized dihydrotestosterone (DHT)-induced transcriptional activity on the yeast-based androgen receptor gene transcription assay (YAA). Dihydrotestosterone 29-48 androgen receptor Mus musculus 107-124 11985887-2 2002 It competitively antagonized dihydrotestosterone (DHT)-induced transcriptional activity on the yeast-based androgen receptor gene transcription assay (YAA). Dihydrotestosterone 50-53 androgen receptor Mus musculus 107-124 11524240-9 2001 Additionally, activation of MMTV promoter activity by DHT in LbetaT2 cells was diminished by the AR antagonists casodex and 2-hydroxy-flutamide, indicating that the effects of DHT are mediated through AR. Dihydrotestosterone 54-57 androgen receptor Mus musculus 97-99 11524240-9 2001 Additionally, activation of MMTV promoter activity by DHT in LbetaT2 cells was diminished by the AR antagonists casodex and 2-hydroxy-flutamide, indicating that the effects of DHT are mediated through AR. Dihydrotestosterone 54-57 androgen receptor Mus musculus 201-203 11524240-9 2001 Additionally, activation of MMTV promoter activity by DHT in LbetaT2 cells was diminished by the AR antagonists casodex and 2-hydroxy-flutamide, indicating that the effects of DHT are mediated through AR. Dihydrotestosterone 176-179 androgen receptor Mus musculus 97-99 11999320-1 2001 A role for 5alpha-reduction in androgen physiology was first established with the recognition that dihydrotestosterone, the 5alpha-reduced metabolite of testosterone, is formed in many androgen target tissues, binds to the androgen receptor with greater affinity than testosterone, and plays an essential role in virilization of the urogenital sinus and urogenital tubercle during male development. Dihydrotestosterone 99-118 androgen receptor Mus musculus 223-240 1334007-0 1992 Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Dihydrotestosterone 17-44 androgen receptor Mus musculus 75-92 10590174-6 1999 In the present study, whether AR was differentially regulated by the natural agonists T and dihydrotestosterone (DHT) or the nonsteroidal antagonist flutamide (FLU) was assessed. Dihydrotestosterone 92-111 androgen receptor Mus musculus 30-32 10590174-6 1999 In the present study, whether AR was differentially regulated by the natural agonists T and dihydrotestosterone (DHT) or the nonsteroidal antagonist flutamide (FLU) was assessed. Dihydrotestosterone 113-116 androgen receptor Mus musculus 30-32 10590174-9 1999 Treatment with T or DHT significantly augmented AR 3 and 7 h after hormone administration, but only DHT sustained this increase for 21 h. This difference also was observed when males were given T plus finasteride (FIN, a 5alpha reductase inhibitor). Dihydrotestosterone 20-23 androgen receptor Mus musculus 48-50 10590174-12 1999 When administered concomitantly with T or DHT, it effectively inhibited the augmentation of AR normally seen 3 h after androgen treatment. Dihydrotestosterone 42-45 androgen receptor Mus musculus 92-94 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Dihydrotestosterone 64-67 androgen receptor Mus musculus 77-79 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Dihydrotestosterone 64-67 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Dihydrotestosterone 64-67 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Dihydrotestosterone 64-67 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Dihydrotestosterone 64-67 androgen receptor Mus musculus 248-250 18406296-2 1998 Testosterone is the major active androgen circulating in blood, but in many tissues it is metabolized by 5alpha-reductase to 5alpha-dihydrotestosterone, which binds to and activates the androgen receptor. Dihydrotestosterone 125-151 androgen receptor Mus musculus 186-203 7981221-0 1994 The mouse androgen receptor gene contains a second functional promoter which is regulated by dihydrotestosterone. Dihydrotestosterone 93-112 androgen receptor Mus musculus 10-27 7981221-1 1994 The androgen receptor (AR) is a developmental and tissue-specific transcription factor which is activated by binding testosterone or dihydrotestosterone. Dihydrotestosterone 133-152 androgen receptor Mus musculus 4-21 7981221-1 1994 The androgen receptor (AR) is a developmental and tissue-specific transcription factor which is activated by binding testosterone or dihydrotestosterone. Dihydrotestosterone 133-152 androgen receptor Mus musculus 23-25 35267218-3 2022 Chronic exposure of female mice to dihydrotestosterone (DHT) from 3 weeks of age drives both reproductive and metabolic impairments that are ameliorated by selective androgen receptor (AR) loss from the brain. Dihydrotestosterone 35-54 androgen receptor Mus musculus 166-183 2293028-4 1990 These data suggested that the androgen receptor-independent induction of KAP gene expression in these animals was mediated by an estrogenic metabolite of testosterone, since dihydrotestosterone cannot be aromatized to an estrogenic form. Dihydrotestosterone 174-193 androgen receptor Mus musculus 30-47 34864817-6 2021 Moreover, eIF5A2 knockdown could eliminate DHT-induced invasion and migration of AR-positive PCa cells. Dihydrotestosterone 43-46 androgen receptor Mus musculus 81-83 34547140-4 2021 Hyperandrogenemia in a dihydrotestosterone (DHT)-treated female mouse model induces whole body insulin resistance possibly through activation of the hepatic androgen receptor (AR). Dihydrotestosterone 23-42 androgen receptor Mus musculus 157-174 34547140-4 2021 Hyperandrogenemia in a dihydrotestosterone (DHT)-treated female mouse model induces whole body insulin resistance possibly through activation of the hepatic androgen receptor (AR). Dihydrotestosterone 23-42 androgen receptor Mus musculus 176-178 34547140-4 2021 Hyperandrogenemia in a dihydrotestosterone (DHT)-treated female mouse model induces whole body insulin resistance possibly through activation of the hepatic androgen receptor (AR). Dihydrotestosterone 44-47 androgen receptor Mus musculus 157-174 34547140-4 2021 Hyperandrogenemia in a dihydrotestosterone (DHT)-treated female mouse model induces whole body insulin resistance possibly through activation of the hepatic androgen receptor (AR). Dihydrotestosterone 44-47 androgen receptor Mus musculus 176-178 35267218-3 2022 Chronic exposure of female mice to dihydrotestosterone (DHT) from 3 weeks of age drives both reproductive and metabolic impairments that are ameliorated by selective androgen receptor (AR) loss from the brain. Dihydrotestosterone 35-54 androgen receptor Mus musculus 185-187 35267218-3 2022 Chronic exposure of female mice to dihydrotestosterone (DHT) from 3 weeks of age drives both reproductive and metabolic impairments that are ameliorated by selective androgen receptor (AR) loss from the brain. Dihydrotestosterone 56-59 androgen receptor Mus musculus 166-183 35267218-3 2022 Chronic exposure of female mice to dihydrotestosterone (DHT) from 3 weeks of age drives both reproductive and metabolic impairments that are ameliorated by selective androgen receptor (AR) loss from the brain. Dihydrotestosterone 56-59 androgen receptor Mus musculus 185-187 35267218-11 2022 Chronic DHT exposure significantly increased the number of AR expressing cells in the hypothalamus, whereas oestrogen receptor alpha-expressing neuron number was unchanged. Dihydrotestosterone 8-11 androgen receptor Mus musculus 59-61 35267218-12 2022 Therefore, although chronic DHT exposure from 3 weeks of age increases AR expressing neurons in the brain, the GnRH neuronal network changes and hyperactive LH secretion associated with prenatal androgen excess are not evident. Dihydrotestosterone 28-31 androgen receptor Mus musculus 71-73 35018219-9 2022 Concordantly, DHT treatment induced nuclear interactions between AR and Sp1 or Sp3. Dihydrotestosterone 14-17 androgen receptor Mus musculus 65-67